Identification of active components in Xuefu Zhuyu Decoction based on targets of blood-activating function.
10.19540/j.cnki.cjcmm.20210830.401
- Author:
Jing MA
1
;
Yue REN
1
;
Bo-Wen ZHAO
1
;
Li LIN
2
;
Yan-Ling ZHANG
1
Author Information
1. Engineering Research Center of Key Technologies for Traditional Chinese Medicine Pharmacy and New Drug Development of Ministry of Education, Research Center of Traditional Chinese Medicine-Information Engineering of National Administration of Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 102488,China.
2. Beijing Key Laboratory of Pharmacology of Chinese Materia Medica, Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
- Publication Type:Journal Article
- Keywords:
Xuefu Zhuyu Decoction;
active components group;
blood-activating function;
molecular docking
- MeSH:
Drugs, Chinese Herbal/pharmacology*;
Medicine, Chinese Traditional;
Molecular Docking Simulation;
Network Pharmacology;
Rhizome
- From:
China Journal of Chinese Materia Medica
2021;46(23):6243-6250
- CountryChina
- Language:Chinese
-
Abstract:
As a classic prescription for promoting blood circulation to remove blood stasis, Xuefu Zhuyu Decoction(XFZYD) is widely used in clinical practice and has notable curative effect. Based on the key targets of activating blood circulation, this study identified the active components of XFZYD to reveal the material basis. The components of XFZYD were collected from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP). The molecular docking models were built for the blood-activating targets obtained from the previous study with the components of XFZYD. The top five active components with measurability for each target were selected as the potential blood-activating components in the prescription. The efficacy of the prescription can embody key pharmacological and high-content components. In this study, anti-platelet aggregation activity was used to characterize the effect of activating blood, and the in vivo experiments were conducted to verify the accuracy of the active components. A total of 210 chemical components of XFZYD were screened out from TCMSP and docked with the key targets with the function of activating blood. Ligustrazine, acteoside, naringin, etc. were selected as the potential active components for activating blood in XFZYD. The anti-platelet aggregation activity of the combination of Chuanxiong Rhizoma, Rehmanniae Radix, Aurantii Fructus, Glycyrrhizae Radix et Rhizoma, and Carthami Flos was 9.82%±5.11%. Compared with that in the control group, the platelet aggregation induced by adenosine diphosphate(ADP) was significantly inhibited in the test group(P<0.01), which verified the accuracy of the active components. This study can guide the research on the material basis of XFZYD and provide insights into the development and utilization of the classical prescription.
